Texas Capital Bank Wealth Management Services Inc Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 13,885 shares of the company’s stock after purchasing an additional 1,958 shares during the quarter. Eli Lilly and Company comprises about 1.3% of Texas Capital Bank Wealth Management Services Inc’s holdings, making the stock its 11th biggest holding. Texas Capital Bank Wealth Management Services Inc’s holdings in Eli Lilly and Company were worth $12,571,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Aveo Capital Partners LLC grew its stake in shares of Eli Lilly and Company by 8.2% in the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after acquiring an additional 153 shares during the period. Gryphon Financial Partners LLC grew its holdings in shares of Eli Lilly and Company by 19.4% in the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after acquiring an additional 377 shares during the period. J. W. Coons Advisors LLC lifted its holdings in Eli Lilly and Company by 4.0% in the fourth quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after acquiring an additional 90 shares during the period. Relative Value Partners Group LLC lifted its holdings in Eli Lilly and Company by 3.5% in the fourth quarter. Relative Value Partners Group LLC now owns 1,791 shares of the company’s stock valued at $1,044,000 after acquiring an additional 60 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Brown Brothers Harriman & Co. now owns 17,074 shares of the company’s stock valued at $9,953,000 after purchasing an additional 80 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Barclays upped their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the sale, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 423,559 shares of company stock valued at $393,136,808 over the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 3.5 %

Shares of NYSE LLY opened at $877.50 on Friday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The business has a fifty day simple moving average of $896.10 and a two-hundred day simple moving average of $842.91. The firm has a market cap of $833.98 billion, a PE ratio of 129.23, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.